Investigational Site Number :1560004

Shanghai 200080

3 studies enrolling now · 6 studies all time

What they study most

Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Hidradenitis Suppurativa, Plasma Cell Myeloma, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
• A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa — Recruiting now
• Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) — Stopped early
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea — Stopped early